Comparison of Serum SIRT-1 and MMP-9 Levels of Patients With Bronchiectasis and Healthy Controls

Not Applicable

Completed

• Conditions: Bronchiectasis Adult
• Interventions: Diagnostic Test: Measurement of MMP-9 and SIRT-1 levels in blood serum

• Registration Number: NCT06589492
• Lead Sponsor: Cumhuriyet University

Brief Summary

The purpose of this a cross-sectinol study is to measure the levels of MMP-9 and SIRT-1 levels in patients with bronchiectasis and healthy controls. The aim is to compare the serum levels of these molecules between patients and controls.

* Is the MMP-9 level increasing or decreasing?

* Is the SIRT-1 level increasing or decreasing in patients?

* Is the disease related to age and gender? Participants will only have one 5 ml blood sample drawn when they visit the chest illness clinic. Molecule levels will be measured in this blood's serum.

The patient group participants will be scanned once with high-resolution chest CT.

Apart from this, comparisons will be made using the age and gender information of the participants.

Detailed Description

In the overall study population of 60 subjects who applied to the Sivas Cumhuriyet University Faculty of Medicine Research and Practice Hospital Chest Diseases Clinic. The study population was selected regardless of age and gender. Participants selected bronchiectasis patients (n=30) who had symptoms (cough, sputum production) and had their diagnosis confirmed by a chest high-resolution CT scan within the previous year. The study excluded individuals with bronchiectasis not associated with cystic fibrosis and who had a worsening episode (according to the 2017 European Respiratory Society expert consensus criteria) (16) or had taken antibiotics during the previous four weeks. The study enrolled healthy controls (n=30) through advertisements who had acceptable chest X-ray and spirometry results and no lower airway symptoms or serious systemic disorders. The study eliminated individuals who were pregnant or nursing, as well as those with low comprehension. SIRT-1 and MMP-9 levels in the serum of the study group were determined by the ELISA method.

Study Timeline

• Study Start: 2020-11-02
• Primary Completion: 2022-09-02
• Study Completion: 2022-09-02
• Status Verified: 2024-09
• Study First Submitted: 2024-09-04
• Study First Submitted QC: 2024-09-09
• Last Update Submitted: 2024-09-09
• Study First Posted: 2024-09-10
• Last Update Posted: 2024-09-10

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• Bronchiectasis patients who were symptoms (cough, sputum production)
• Individuals whose diagnosis was confirmed by a high-resolution chest CT scan taken within the previous year

Exclusion Criteria

• Individuals with bronchiectasis associated with cystic fibrosis and who had a worsening episode
• individuals who were pregnant or nursing
• those with low comprehension
• taken antibiotics during the previous four weeks

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Measurement of MMP-9 and SIRT-1 levels in blood serum	Measurement of MMP-9 and SIRT-1 levels in blood serum	It involves taking 5ml of blood from participants to measure mmp-9 and SIRT-1 levels in blood serum.

Primary Outcome Measures

Name	Time	Method
MMP-9 and SIRT-1 levels (ng/mL) mesurment in the blood serum to compare between patient and control.	not measured in time frame. general (1. day)	MMP-9 and SIRT-1 levels mesured in the blood serum. The most common side effect when blood is taken from the patient is slight bruising and swelling in the arm due to needle sticking. There will be no other serious side effects.

Trial Locations

Locations (1)

Cumhuriyet University; 🇹🇷 Si̇vas, Si̇vas Centre, Turkey